Muscular Diseases Therapies Developer Dyne Therapeutics Files for $100 Million US IPO
Dyne Therapeutics Inc, a muscular disease therapies developer, has filed Form S-1 Registration Statement on August 25, 2020 with U.S Securities and Exchange Commission to raise up to $100 million IPO. Pricing terms are yet to announce.
The company designed its proprietary FORCE platform to overcome current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. Their initial focus programs on potential pipeline expansion opportunities in additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle disease.
The Waltham, Massachusetts-based company was founded in 2017. It plans to list on the Nasdaq Global Market under the symbol “DYN.” J.P. Morgan, Jefferies, Piper Sandler, and Stifel are underwriters of the IPO.
The company engages Wilmer Cutler Pickering Hale and Dorr LLP as US Securities Counsel, and Deloitte & Touche LLP as Independent Auditor.
#ipo #nasdaq #deloitte #muscledisease #healthcare #therapydeveloper
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
